Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (319)	9/2/1999 10:57:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

RWR: Last night my hard was broken! :( For the third time REGN didn't have luck with drug candidate. Before I said any stupid comments I will wait for additional data on Axokine low-dose efficiency versus toxicity. Buying opportunity? First, I do not recommend any stock. Other people are paid for this. Second, depend on the angle. REGN continue to be very low risk stock. Period. Upward potential is now bit cloud. Period. However, if you believe in REGN science and business plan (as S, V and Y do....significant buyers for last few months), than answer is obvious. I have anticipated good Axokine results and consequently was aggressively baying stock in last few months (in addition to my 3 years long holding). So, my portfolio exposure to REGN exceeded pre-set allowance. I am looking to reduce my REGN holding to regular level. Miljenko